Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
| Title: | Small interfering RNA for cancer treatment: overcoming hurdles in delivery. |
|---|---|
| Authors: | Charbe NB; Departamento de Quimica Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.; Sri Adichunchunagiri College of Pharmacy, Sri Adichunchunagiri University, BG Nagar, Karnataka 571418, India.; Amnerkar ND; Adv V. R. Manohar Institute of Diploma in Pharmacy, Nagpur, Maharashtra 441110, India.; Ramesh B; Sri Adichunchunagiri College of Pharmacy, Sri Adichunchunagiri University, BG Nagar, Karnataka 571418, India.; Tambuwala MM; School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine, Northern Ireland BT52 1SA, UK.; Bakshi HA; School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine, Northern Ireland BT52 1SA, UK.; Aljabali AAA; Faculty of Pharmacy, Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid 21163, Jordan.; Khadse SC; Department of Pharmaceutical Chemistry, R.C. Patel Institute of Pharmaceutical Education and Research, Dist. Dhule, Maharashtra 425 405, India.; Satheeshkumar R; Departamento de Quimica Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.; Satija S; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia.; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411 Punjab, India.; Metha M; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia.; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411 Punjab, India.; Chellappan DK; Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia.; Shrivastava G; Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology, Delhi, New Delhi 110016, India.; Gupta G; School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur 302017, India.; Negi P; School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan 173229, India.; Dua K; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia.; School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan 173229, India.; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) and School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW 2308, Australia.; Zacconi FC; Departamento de Quimica Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.; Institute for Biological and Medical Engineering, Schools of Engineering, Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 4860, Chile. |
| Source: | Acta pharmaceutica Sinica. B [Acta Pharm Sin B] 2020 Nov; Vol. 10 (11), pp. 2075-2109. Date of Electronic Publication: 2020 Oct 13. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101600560 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2211-3835 (Print) Linking ISSN: 22113835 NLM ISO Abbreviation: Acta Pharm Sin B Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: [Amsterdam] : Elsevier, 2011- |
| Abstract: | In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies.; (© 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.) |
| Competing Interests: | The authors have no conflicts of interest to declare. |
| References: | Vet J. 2015 Apr;204(1):60-5. (PMID: 25773167); J Am Chem Soc. 2015 Dec 23;137(50):15608-11. (PMID: 26648391); J Gen Virol. 2014 Aug;95(Pt 8):1712-1722. (PMID: 24828333); J Drug Target. 2018 Jun - Jul;26(5-6):398-406. (PMID: 29258343); J Control Release. 2006 Nov 28;116(2):255-64. (PMID: 16914222); Mediators Inflamm. 2002 Jun;11(3):141-8. (PMID: 12137242); Chem Rev. 2015 Jun 10;115(11):5274-300. (PMID: 25944558); J Control Release. 2000 Mar 1;65(1-2):271-84. (PMID: 10699287); Dig Dis Sci. 2009 Jan;54(1):89-96. (PMID: 18594980); J Am Chem Soc. 2012 Oct 10;134(40):16488-91. (PMID: 23020598); Pharm Res. 2008 Dec;25(12):2807-14. (PMID: 18563539); J Control Release. 2011 Oct 10;155(1):18-25. (PMID: 20800628); Cancer Res. 2009 Aug 15;69(16):6531-8. (PMID: 19654315); Nanomedicine. 2020 Jun;26:102176. (PMID: 32151748); J Invest Dermatol. 2010 Dec;130(12):2790-8. (PMID: 20686495); Methods Mol Biol. 2017;1632:231-240. (PMID: 28730443); Exp Biol Med (Maywood). 2009 Feb;234(2):123-31. (PMID: 19064945); J Med Chem. 2001 Oct 25;44(22):3750-3. (PMID: 11606140); Drug Deliv. 2002 Jul-Sep;9(3):161-7. (PMID: 12396733); J Biol Chem. 2005 Jan 7;280(1):826-31. (PMID: 15485892); J Control Release. 2003 Jan 17;86(2-3):349-59. (PMID: 12526830); Drug Metab Dispos. 2018 Jan;46(1):2-10. (PMID: 29061583); Nat Med. 1995 Jan;1(1):39-46. (PMID: 7584951); Small. 2012 Nov 5;8(21):3253-6. (PMID: 22887809); Science. 2006 May 19;312(5776):1027-30. (PMID: 16709779); ACS Nano. 2008 Jul;2(7):1403-10. (PMID: 19206308); Nano Lett. 2009 Jan;9(1):308-11. (PMID: 19099465); Adv Drug Deliv Rev. 2010 Apr 30;62(6):633-49. (PMID: 20338203); Expert Rev Mol Diagn. 2005 Nov;5(6):893-905. (PMID: 16255631); Drug Des Devel Ther. 2019 Feb 22;13:757-766. (PMID: 30863015); Oncol Lett. 2012 Apr 1;3(4):879-884. (PMID: 22741011); Mol Biol Rep. 2010 Jul;37(6):2919-26. (PMID: 19816791); J Control Release. 2018 Apr 10;275:107-116. (PMID: 29452131); Nature. 2004 Mar 25;428(6981):431-7. (PMID: 15042092); ACS Nano. 2016 Feb 23;10(2):1845-52. (PMID: 26811943); Drug Discov Today. 2006 Sep;11(17-18):812-8. (PMID: 16935749); Mol Med. 2007 Nov-Dec;13(11-12):567-75. (PMID: 17873971); Mol Pharm. 2009 May-Jun;6(3):696-705. (PMID: 19267451); Nat Rev Drug Discov. 2004 Dec;3(12):1023-35. (PMID: 15573101); Chem Soc Rev. 2009 Jun;38(6):1759-82. (PMID: 19587967); Int J Pharm. 2010 Nov 15;400(1-2):194-200. (PMID: 20801205); Oncol Lett. 2012 Jan;3(1):135-140. (PMID: 22740869); Bioconjug Chem. 1999 Nov-Dec;10(6):1068-74. (PMID: 10563777); J Clin Invest. 2009 Mar;119(3):661-73. (PMID: 19229107); Expert Opin Drug Deliv. 2013 Nov;10(11):1497-513. (PMID: 23930949); Int J Pharm. 2009 Feb 9;367(1-2):195-203. (PMID: 18940242); Int J Nanomedicine. 2013;8:3271-83. (PMID: 24023515); Eur J Pharm Biopharm. 2019 Mar;136:18-28. (PMID: 30633973); Int J Pharm. 2010 Jun 15;392(1-2):201-8. (PMID: 20214964); Science. 2004 Sep 3;305(5689):1434-7. (PMID: 15284453); Biomaterials. 2014 Oct;35(30):8621-34. (PMID: 25002258); ACS Nano. 2011 Jun 28;5(6):5202-13. (PMID: 21627074); J Phys Condens Matter. 2017 May 24;29(20):203002. (PMID: 28426435); J Gene Med. 2009 Sep;11(9):791-803. (PMID: 19569085); BMC Cancer. 2012 Sep 22;12:420. (PMID: 22998564); Gene Ther. 2006 Aug;13(16):1222-34. (PMID: 16625243); J Drug Target. 2019 Feb;27(2):217-227. (PMID: 30024300); Nat Commun. 2014 Mar 12;5:3459. (PMID: 24619206); Sci Transl Med. 2013 Oct 30;5(209):209ra152. (PMID: 24174328); Ann N Y Acad Sci. 2006 Oct;1082:1-8. (PMID: 17145918); Anticancer Res. 2019 Mar;39(3):1169-1178. (PMID: 30842146); Proc Natl Acad Sci U S A. 1987 Nov;84(21):7413-7. (PMID: 2823261); Trends Biochem Sci. 2005 Feb;30(2):106-14. (PMID: 15691656); Nucleic Acids Res. 2004 Mar 16;32(5):e48. (PMID: 15026537); J Nucl Med Technol. 2007 Dec;35(4):213-25; quiz 226-8. (PMID: 18006597); Naunyn Schmiedebergs Arch Pharmacol. 2013 Apr;386(4):287-302. (PMID: 23354452); Biomed Res Int. 2013;2013:574136. (PMID: 23865058); Biochem Pharmacol. 2019 Aug;166:192-202. (PMID: 31129050); Sci Rep. 2018 May 14;8(1):7498. (PMID: 29760419); Onco Targets Ther. 2018 Jun 06;11:3359-3368. (PMID: 29922074); Small. 2011 Nov 18;7(22):3158-62. (PMID: 21922667); Nature. 2004 Nov 11;432(7014):173-8. (PMID: 15538359); Mol Ther Nucleic Acids. 2013 Dec 03;2:e136. (PMID: 24301867); Mol Ther. 2014 Feb;22(2):359-370. (PMID: 24002693); Molecules. 2017 Aug 31;22(9):. (PMID: 28858253); ACS Nano. 2012 Jan 24;6(1):771-81. (PMID: 22136582); ACS Nano. 2012 Jun 26;6(6):5174-89. (PMID: 22575090); J Am Chem Soc. 2008 Apr 23;130(16):5430-1. (PMID: 18370386); Trends Biochem Sci. 2016 Mar;41(3):211-218. (PMID: 26778478); Mol Ther. 2002 Apr;5(4):463-72. (PMID: 11945074); Chemistry. 2017 May 11;23(27):6586-6595. (PMID: 28218434); Int J Pharm. 2010 May 5;390(1):70-5. (PMID: 19836438); Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):47-69. (PMID: 22097965); J Am Chem Soc. 2003 Feb 12;125(6):1643-54. (PMID: 12568626); Contrast Media Mol Imaging. 2014 Jan-Feb;9(1):53-61. (PMID: 24470294); J Cell Physiol. 2020 Mar;235(3):2049-2059. (PMID: 31364167); Cancer Res. 1996 Mar 15;56(6):1194-8. (PMID: 8640796); ACS Nano. 2011 Aug 23;5(8):6138-47. (PMID: 21739990); J Cell Mol Med. 2008 Dec;12(6A):2334-49. (PMID: 18266952); Mol Ther Nucleic Acids. 2018 Sep 7;12:805-816. (PMID: 30153565); Mol Ther. 2014 Jun;22(6):1075-1083. (PMID: 24599278); J Anat. 1996 Dec;189 ( Pt 3):503-5. (PMID: 8982823); ACS Appl Mater Interfaces. 2016 May 18;8(19):12063-74. (PMID: 27128684); Nat Biotechnol. 2008 Aug;26(8):933-40. (PMID: 18641635); ACS Cent Sci. 2018 Oct 24;4(10):1326-1333. (PMID: 30410970); Bioconjug Chem. 2009 Nov;20(11):2055-61. (PMID: 19835410); J Control Release. 2006 Jun 28;113(2):155-63. (PMID: 16764960); Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21. (PMID: 17379663); Mater Sci Eng C Mater Biol Appl. 2017 Nov 1;80:18-28. (PMID: 28866154); Int J Pharm. 2005 Sep 14;301(1-2):277-85. (PMID: 16019173); Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12. (PMID: 9539785); J Biomed Nanotechnol. 2016 Oct;12(10):1952-61. (PMID: 29360338); Nature. 2001 May 24;411(6836):494-8. (PMID: 11373684); Biomaterials. 2011 Jun;32(18):4306-16. (PMID: 21429576); Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):E6490-E6497. (PMID: 28739942); Nat Biotechnol. 2005 Aug;23(8):1002-7. (PMID: 16041363); Mol Pharm. 2009 Nov-Dec;6(6):1934-40. (PMID: 19810673); ACS Appl Mater Interfaces. 2013 Aug 14;5(15):7227-35. (PMID: 23815498); Curr Protoc Nucleic Acid Chem. 2009 Dec;Chapter 16:Unit 16.3. (PMID: 20013783); ACS Nano. 2013 Mar 26;7(3):1918-28. (PMID: 23411462); Biomaterials. 2016 Apr;86:92-105. (PMID: 26896610); Nucleic Acid Ther. 2011 Jun;21(3):133-47. (PMID: 21749290); Mol Cell. 2003 Sep;12(3):627-37. (PMID: 14527409); Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11975-80. (PMID: 22773805); Nanomedicine. 2012 Jul;8(5):692-701. (PMID: 22024191); Nat Cell Biol. 2005 Jun;7(6):591-600. (PMID: 15864305); J Am Chem Soc. 2005 Sep 21;127(37):12754-5. (PMID: 16159241); Nucleic Acids Res. 2004 Nov 01;32(19):e149. (PMID: 15520458); Integr Biol (Camb). 2013 Jan;5(1):96-107. (PMID: 22869005); Biochemistry. 2004 Oct 26;43(42):13348-56. (PMID: 15491141); J Gene Med. 2007 Aug;9(8):659-67. (PMID: 17611953); Mater Sci Eng C Mater Biol Appl. 2017 Jul 1;76:659-672. (PMID: 28482576); J Control Release. 2009 Aug 4;137(3):234-40. (PMID: 19361546); Mol Pharm. 2013 Mar 4;10(3):975-87. (PMID: 23331322); Anticancer Res. 2011 Sep;31(9):2813-20. (PMID: 21868524); Acc Chem Res. 2012 Jul 17;45(7):1163-71. (PMID: 22568781); Cancer Res. 2005 Oct 1;65(19):8984-92. (PMID: 16204072); Nanoscale. 2014 Sep 7;6(17):10084-94. (PMID: 25032749); Biomaterials. 2010 Jul;31(21):5671-7. (PMID: 20434215); Int J Nanomedicine. 2008;3(1):21-9. (PMID: 18488413); Cell J. 2015 Summer;17(2):273-87. (PMID: 26199906); J Drug Target. 2017 Jun;25(5):451-462. (PMID: 28110554); Int J Biomed Sci. 2017 Jun;13(2):48-57. (PMID: 28824341); Adv Healthc Mater. 2018 Oct;7(20):e1800685. (PMID: 30240152); Molecules. 2014 Aug 28;19(9):13319-31. (PMID: 25170952); Pharm Res. 1996 Feb;13(2):202-9. (PMID: 8932437); Adv Funct Mater. 2015 May 13;25(18):2646-2659. (PMID: 26097445); Bioconjug Chem. 2003 Nov-Dec;14(6):1122-32. (PMID: 14624625); Yonsei Med J. 2008 Apr 30;49(2):295-300. (PMID: 18452268); J Control Release. 2016 Dec 28;244(Pt B):194-204. (PMID: 27374187); Mol Pharm. 2018 Jan 2;15(1):53-62. (PMID: 29148802); J Mol Biol. 1964 May;8:660-8. (PMID: 14187392); Mol Pharm. 2009 May-Jun;6(3):706-17. (PMID: 19159285); Biomaterials. 2006 Jun;27(16):3147-53. (PMID: 16469375); J Control Release. 2010 Dec 1;148(2):135-46. (PMID: 20797419); Biomed Pharmacother. 2018 Dec;108:584-589. (PMID: 30243092); Biomaterials. 2013 May;34(14):3647-57. (PMID: 23415642); Biol Res. 2018 Dec 29;51(1):58. (PMID: 30594239); Curr Top Med Chem. 2008;8(4):331-40. (PMID: 18393895); Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11307-11. (PMID: 8248244); Int J Pharm. 2013 Aug 30;453(1):198-214. (PMID: 22944304); Front Pharmacol. 2014 Apr 25;5:77. (PMID: 24795633); Macromol Biosci. 2010 Mar 10;10(3):239-45. (PMID: 19924685); J Control Release. 2010 Jul 14;145(2):159-64. (PMID: 20385182); Int J Pharm. 2013 Sep 15;454(1):486-95. (PMID: 23792465); Nature. 2006 May 4;441(7089):111-4. (PMID: 16565705); Cell. 2001 Nov 2;107(3):309-21. (PMID: 11701122); Proc Natl Acad Sci U S A. 1991 May 15;88(10):4255-9. (PMID: 2034670); Biochem Biophys Res Commun. 2018 Sep 10;503(3):1716-1722. (PMID: 30049442); Nat Rev Genet. 2014 Aug;15(8):541-55. (PMID: 25022906); Int J Clin Exp Med. 2015 Jan 15;8(1):634-41. (PMID: 25785038); Oncogene. 2006 Mar 2;25(9):1340-8. (PMID: 16247451); J Am Coll Surg. 2004 Jun;198(6):953-9. (PMID: 15194078); Artif Cells Nanomed Biotechnol. 2016 Nov;44(7):1589-96. (PMID: 26497011); J Drug Target. 2003 Jul;11(6):311-23. (PMID: 14668052); Int J Pharm. 2009 Mar 18;369(1-2):144-54. (PMID: 19010405); Biomaterials. 2010 Aug;31(24):6344-54. (PMID: 20537703); J Gene Med. 2010 Sep;12(9):729-38. (PMID: 20683834); Nat Nanotechnol. 2014 Nov;9(11):907-912. (PMID: 25282044); Int J Nanomedicine. 2019 Apr 15;14:2637-2653. (PMID: 31043779); Cell Physiol Biochem. 2018;46(4):1365-1380. (PMID: 29689552); J Control Release. 2020 Jun 10;322:81-94. (PMID: 32173328); Mol Pharm. 2009 Nov-Dec;6(6):1826-35. (PMID: 19791796); J Pharmacol Sci. 2019 Mar;139(3):231-239. (PMID: 30803892); Nat Biotechnol. 2009 Oct;27(10):925-32. (PMID: 19749770); Nano Lett. 2009 May;9(5):2059-64. (PMID: 19331425); Bioconjug Chem. 2006 Sep-Oct;17(5):1209-18. (PMID: 16984130); Adv Drug Deliv Rev. 2009 Jul 25;61(9):746-59. (PMID: 19389436); J Am Chem Soc. 2016 Apr 6;138(13):4616-25. (PMID: 26958699); Cancer Biother Radiopharm. 2005 Apr;20(2):141-9. (PMID: 15869447); Acc Chem Res. 2012 Jul 17;45(7):1122-31. (PMID: 22304792); ACS Appl Mater Interfaces. 2019 Oct 30;11(43):39513-39524. (PMID: 31599562); Anal Chem. 2005 Dec 15;77(24):8174-8. (PMID: 16351173); Pharmacol Res. 2010 Aug;62(2):90-9. (PMID: 20380880); Biomaterials. 2014 Apr;35(12):3840-50. (PMID: 24486214); Mater Sci Eng C Mater Biol Appl. 2018 Apr 1;85:130-141. (PMID: 29407141); Adv Drug Deliv Rev. 2009 Aug 10;61(10):850-62. (PMID: 19422869); Medchemcomm. 2019 Jun 18;10(7):1138-1144. (PMID: 31391886); J Control Release. 2009 Dec 16;140(3):277-83. (PMID: 19699770); Hum Gene Ther. 2006 Jan;17(1):117-24. (PMID: 16409130); World J Gastroenterol. 2014 Jul 7;20(25):8229-36. (PMID: 25009397); Hum Gene Ther. 1993 Dec;4(6):781-8. (PMID: 8186291); Pharmaceutics. 2019 Feb 21;11(2):. (PMID: 30795589); Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14717-22. (PMID: 23959886); Nanomedicine. 2010 Dec;6(6):714-29. (PMID: 20542144); Nucleic Acids Res. 2018 Mar 16;46(5):2185-2196. (PMID: 29432571); Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):164-82. (PMID: 17481774); Pharm Res. 2000 May;17(5):521-5. (PMID: 10888302); Proc Natl Acad Sci U S A. 1989 Sep;86(18):6982-6. (PMID: 2780554); Biomacromolecules. 2018 Jun 11;19(6):2194-2201. (PMID: 29684275); Nat Rev Drug Discov. 2007 Jun;6(6):443-53. (PMID: 17541417); Artif Cells Nanomed Biotechnol. 2018 Dec;46(8):1792-1798. (PMID: 29113504); Eur J Pharm Biopharm. 2011 Jan;77(1):26-35. (PMID: 21093589); Int J Pharm. 2007 Sep 5;342(1-2):33-9. (PMID: 17566677); J Int Med Res. 2008 Jul-Aug;36(4):734-47. (PMID: 18652770); Cancer Sci. 2006 Oct;97(10):1115-24. (PMID: 16984384); Bioconjug Chem. 2010 Dec 15;21(12):2250-6. (PMID: 21070003); Cancer Res. 2006 Jul 1;66(13):6732-40. (PMID: 16818648); Nano Lett. 2007 Dec;7(12):3818-21. (PMID: 17997588); Nano Lett. 2012 Jan 11;12(1):287-92. (PMID: 22165988); Nat Rev Genet. 2011 Feb;12(2):99-110. (PMID: 21245828); Mol Ther. 2010 Apr;18(4):828-34. (PMID: 20068551); Biomacromolecules. 2013 Dec 9;14(12):4407-19. (PMID: 24219322); Sci Rep. 2013;3:1553. (PMID: 23531983); Mol Ther. 2008 May;16(5):942-6. (PMID: 18388916); J Control Release. 2012 Mar 28;158(3):362-70. (PMID: 22023849); Biochim Biophys Acta. 1995 May 4;1235(2):289-95. (PMID: 7756337); Lancet. 2010 May 29;375(9729):1896-905. (PMID: 20511019); Biomacromolecules. 2010 Sep 13;11(9):2422-31. (PMID: 20831277); Eur J Pharm Sci. 2019 Jan 15;127:161-174. (PMID: 30366077); Adv Drug Deliv Rev. 2010 Jan 31;62(1):12-27. (PMID: 19796660); Adv Drug Deliv Rev. 1999 Mar 1;36(1):3-16. (PMID: 10837705); Nat Biotechnol. 2005 Jun;23(6):709-17. (PMID: 15908939); Mol Ther. 2008 Jan;16(1):163-9. (PMID: 17923843); Trends Mol Med. 2015 Apr;21(4):223-32. (PMID: 25656384); Hum Exp Toxicol. 2017 Mar;36(3):227-237. (PMID: 27162247); Philos Trans A Math Phys Eng Sci. 2010 Mar 28;368(1915):1333-83. (PMID: 20156828); Nature. 2004 Dec 23;432(7020):1036-40. (PMID: 15616564); Nano Lett. 2009 Jun;9(6):2402-6. (PMID: 19422265); Chem Soc Rev. 2011 Mar;40(3):1586-608. (PMID: 21042619); Acta Biochim Biophys Sin (Shanghai). 2009 Mar;41(3):223-30. (PMID: 19280061); Biochemistry. 1996 Jan 23;35(3):1027-36. (PMID: 8547238); Expert Opin Drug Deliv. 2008 Dec;5(12):1301-11. (PMID: 19040393); Biophys J. 2008 May 15;94(10):3790-7. (PMID: 18234813); Cancer Res. 2004 Feb 15;64(4):1431-5. (PMID: 14973067); Mol Pharm. 2005 May-Jun;2(3):194-205. (PMID: 15934780); Gene Ther. 2007 Apr;14(8):682-9. (PMID: 17268535); Biomaterials. 2010 Sep;31(26):6867-75. (PMID: 20541799); J Control Release. 2018 Oct 10;287:103-120. (PMID: 30144476); Biomaterials. 2014 May;35(16):4688-98. (PMID: 24613050); Biomaterials. 2010 Aug;31(22):5886-93. (PMID: 20427082); Nature. 2003 Aug 14;424(6950):797-801. (PMID: 12917690); Int J Nanomedicine. 2016 Sep 27;11:4931-4945. (PMID: 27729789); Mol Ther. 2006 Oct;14(4):476-84. (PMID: 16829204); Colloids Surf B Biointerfaces. 2013 Jan 1;101:6-13. (PMID: 22789783); Int J Pharm. 2008 Apr 16;354(1-2):210-6. (PMID: 18178349); Expert Opin Drug Deliv. 2016;13(4):547-59. (PMID: 26735861); Nature. 2007 Jul 5;448(7149):39-43. (PMID: 17572664); Sci Rep. 2016 Apr 28;6:25069. (PMID: 27121799); Biomaterials. 2011 May;32(13):3459-70. (PMID: 21296406); Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17047-52. (PMID: 24062440); Macromol Rapid Commun. 2010 Jul 1;31(13):1122-33. (PMID: 21590865); Colloids Surf B Biointerfaces. 2016 Feb 1;138:60-9. (PMID: 26655793); Biosci Rep. 1995 Feb;15(1):47-53. (PMID: 7647291); Cancer Discov. 2013 Apr;3(4):406-17. (PMID: 23358650); Int J Pharm. 2010 May 10;390(2):198-207. (PMID: 20116418); J Control Release. 2008 Jul 14;129(2):107-16. (PMID: 18486981); Cancer Res. 2011 Mar 15;71(6):2240-9. (PMID: 21385903); Eur J Pharm Sci. 2016 Oct 10;93:493-503. (PMID: 27593989); Nanomaterials (Basel). 2018 Apr 24;8(5):. (PMID: 29695068); J Am Chem Soc. 2009 Feb 18;131(6):2072-3. (PMID: 19170493); Eur J Immunol. 2006 Dec;36(12):3256-67. (PMID: 17111347); Eur J Pharm Biopharm. 2012 Aug;81(3):470-7. (PMID: 22579732); Angew Chem Int Ed Engl. 2010 Apr 26;49(19):3280-94. (PMID: 20401880); J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):2821-8. (PMID: 17048488); Oligonucleotides. 2008 Dec;18(4):365-74. (PMID: 18928331); J Drug Deliv. 2012;2012:262731. (PMID: 22496980); Drug Discov Today. 2002 Oct 1;7(19):998-1001. (PMID: 12546917); Cancer Res. 2008 Dec 1;68(23):9788-98. (PMID: 19047158); Adv Mater. 2013 May 21;25(19):2641-60. (PMID: 23553799); J Control Release. 2008 Oct 6;131(1):64-9. (PMID: 18674578); Biomaterials. 2010 Mar;31(7):1798-804. (PMID: 19854504); Nano Lett. 2019 Apr 10;19(4):2688-2693. (PMID: 30844291); BMC Biotechnol. 2002 Jul 12;2:12. (PMID: 12113654); Mol Ther. 2005 Jun;11(6):990-5. (PMID: 15922971); Int J Mol Sci. 2013 Apr 11;14(4):7959-78. (PMID: 23579957); Eur Rev Med Pharmacol Sci. 2014;18(12):1735-41. (PMID: 24992616); Mol Med Rep. 2015 Dec;12(6):7957-62. (PMID: 26497351); Anal Chim Acta. 2012 Nov 2;751:24-43. (PMID: 23084049); Cells. 2015 May 22;4(2):178-201. (PMID: 26010753); Bioconjug Chem. 2019 Feb 20;30(2):305-324. (PMID: 30428665); Biomaterials. 2013 Dec;34(38):10084-98. (PMID: 24060417); J Mater Chem B. 2015 Aug 21;3(31):6448-6455. (PMID: 26413302); Small. 2011 Feb 7;7(3):364-70. (PMID: 21294265); Anal Chem. 2006 Dec 15;78(24):8313-8. (PMID: 17165821); RNA. 2003 Sep;9(9):1034-48. (PMID: 12923253); ACS Nano. 2012 Jun 26;6(6):4955-65. (PMID: 22646867); J Microencapsul. 2005 May;22(3):235-44. (PMID: 16019909); Int J Nanomedicine. 2013;8:1573-93. (PMID: 23637529); Mol Pharm. 2010 Oct 4;7(5):1643-54. (PMID: 20804176); Oncol Rep. 2013 Mar;29(3):1183-8. (PMID: 23254641); Sci Rep. 2019 Mar 18;9(1):4762. (PMID: 30886159); Chem Rev. 2018 Aug 22;118(16):7409-7531. (PMID: 30052023); Oligonucleotides. 2010 Jun;20(3):127-36. (PMID: 20420543); J Control Release. 2007 Apr 23;118(3):357-63. (PMID: 17313987); Nanomedicine (Lond). 2014 Jan;9(1):105-20. (PMID: 24354813); ACS Chem Biol. 2016 Jun 17;11(6):1490-501. (PMID: 27055654); Nat Commun. 2016 Jun 06;7:11822. (PMID: 27264609); Bioconjug Chem. 2002 May-Jun;13(3):630-9. (PMID: 12009955); J Control Release. 2010 Mar 19;142(3):416-21. (PMID: 19919845); Chem Soc Rev. 2005 Mar;34(3):276-85. (PMID: 15726163); J Mater Chem B. 2016 Apr 7;4(13):2242-2252. (PMID: 32263220); Chem Sci. 2018 Oct 4;10(1):284-292. (PMID: 30713638); Int J Pharm. 2009 Jul 6;376(1-2):104-9. (PMID: 19409469); J Med Chem. 2005 Feb 24;48(4):901-4. (PMID: 15715458); Biomaterials. 2015 Sep;63:70-9. (PMID: 26086448); Science. 2002 Sep 20;297(5589):2056-60. (PMID: 12154197); Chem Commun (Camb). 2010 Feb 7;46(5):692-4. (PMID: 20087489); Oncogene. 2004 Feb 26;23(8):1539-48. (PMID: 14661056); Nanomedicine (Lond). 2008 Aug;3(4):555-65. (PMID: 18694317); Biomaterials. 2010 Jan;31(1):133-43. (PMID: 19783041) |
| Contributed Indexing: | Keywords: 1,3-propanediol, PEG-b-PDMAEMA-b-Ppy; 2-propylacrylicacid, PAH-b-PDMAPMA-b-PAH; APOB, apolipoprotein B; AQP-5, aquaporin-5; AZEMA, azidoethyl methacrylate; Atufect01, β-l-arginyl-2,3-l-diaminopropionicacid-N-palmityl-N-oleyl-amide trihydrochloride; AuNPs, gold nanoparticles; B-PEI, branched polyethlenimine; BMA, butyl methacrylate; CFTR, cystic fibrosis transmembrane conductance regulator gene; CHEMS, cholesteryl hemisuccinate; CHOL, cholesterol; CMC, critical micelles concentration; Cancer; DC-Chol, 3β-[N-(N′,N′-dimethylaminoethane)carbamoyl]cholesterol; DMAEMA, 2-dimethylaminoethyl methacrylate; DNA, deoxyribonucleic acid; DOPC, dioleylphosphatidyl choline; DOPE, dioleylphosphatidyl ethanolamine; DOTAP, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate; DOTMA, N-[1-(2,3-dioleyloxy)propy]-N,N,N-trimethylammoniumchloride; DOX, doxorubicin; DSGLA, N,N-dis-tearyl-N-methyl-N-2[N′-(N2-guanidino-l-lysinyl)] aminoethylammonium chloride; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; DSPE, 1,2-distearoyl-sn-glycero-3-phosphorylethanolamine; DSPE-MPEG, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt); DSPE-PEG-Mal: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (mmmonium salt), EPR; Liposomes; Micelles; N-acetylgalactosamine, HIF-1α; Nanomedicine; PE-PCL-b-PNVCL, pentaerythritol polycaprolactone-block-poly(N-vinylcaprolactam); PLA, poly-l-arginine; PLGA, poly lactic-co-glycolic acid; PLK-1, polo-like kinase 1; PLL, poly-l-lysine; PPES-b-PEO-b-PPES, poly(4-(phenylethynyl)styrene)-block-PEO-block-poly(4-(phenylethynyl)styrene); PTX, paclitaxel; PiRNA, piwi-interacting RNA; Polymer; RES, reticuloendothelial system; RGD, Arg-Gly-Asp peptide; RISC, RNA-induced silencing complex; RNA, ribonucleic acid; RNAi, RNA interference; RNAse III, ribonuclease III enzyme; SEM, scanning electron microscope; SNALP, stable nucleic acid-lipid particles; SiRNA, short interfering rNA; Small interfering RNA (siRNA); S–Au, thio‒gold; TCC, transitional cell carcinoma; TEM, transmission electron microscopy; Tf, transferrin; Trka, tropomyosin receptor kinase A; USPIO, ultra-small superparamagnetic iron oxide nanoparticles; UV, ultraviolet; VEGF, vascular endothelial growth factor; ZEBOV, Zaire ebola virus; enhanced permeability and retention, Galnac; hypoxia-inducible factor-1α, KSP; kinesin spindle protein, LDI; lipid-protamine-DNA/hyaluronic acid, MDR; lysine ethyl ester diisocyanate, LPD/LPH; messenger RNA, MTX; methotrexate, NIR; methoxy polyethylene glycol-polycaprolactone, mRNA; methoxypoly(ethylene glycol), MPEG-PCL; micro RNA, MPEG; multiple drug resistance, MiRNA; nanoparticle, NRP-1; near-infrared, NP; neuropilin-1, PAA; poly(N,N-dimethylacrylamide), PDO; poly(N-isopropyl acrylamide), pentaerythritol polycaprolactone-block-poly(N-isopropylacrylamide); poly(acrylhydrazine)-block-poly(3-dimethylaminopropyl methacrylamide)-block-poly(acrylhydrazine), PCL; poly(ethylene glycol)-block-poly(2-dimethylaminoethyl methacrylate)-block poly(pyrenylmethyl methacrylate), PEG-b-PLL; poly(ethylene glycol)-block-poly(l-lysine), PEI; poly(ethylene oxide)-block-poly(2-(diethylamino)ethyl methacrylate)-stat-poly(methoxyethyl methacrylate), PEO-b-PCL; poly(ethylene oxide)-block-poly(Ε-caprolactone), PE-PCL-b-PNIPAM; poly(Ε-caprolactone), PCL-PEG; poly(Ε-caprolactone)-polyethyleneglycol-poly(l-histidine), PCL-PEI; polycaprolactone-polyethyleneglycol, PCL-PEG-PHIS; polycaprolactone-polyethylenimine, PDMA; polyethylenimine, PEO-b-P(DEA-Stat-MEMA |
| Entry Date(s): | Date Created: 20201211 Latest Revision: 20240804 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC7714980 |
| DOI: | 10.1016/j.apsb.2020.10.005 |
| PMID: | 33304780 |
| Database: | MEDLINE |
Journal Article; Review